Stefano Fiorucci

This inventor holds 16 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 7 EPO patents. Top assignees: Intercept Pharmaceuticals, Inc., Antibe Therapeutics Inc., Bar Pharmaceuticals S.r.l.. Active years: 2009-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stefano Fiorucci. Retrieved from https://idiyas.com/inventor/stefano-fiorucci

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 5)

% Patents Active = 50.0

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 3.2

ph-index = 6

Forward Citations = 122(Granted Patents)

Location History:

Perugie, IT (2011)
Perugia, IT (2009 - 2022)

Company Filing History:

8 out of 62

Intercept Pharmaceuticals, Inc.

patents

5 out of 10

Antibe Therapeutics Inc.

patents

2 out of 2

Bar Pharmaceuticals S.r.l.

patents

4. 1 out of 1

Bar Pharmaceuticals Societa' a Responsabilita' Limitata

patent

Years Active: 2009-2022

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11332450 - Isoxazole as FXR receptor agonists (2022-05-17),

2. 11117926 - Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases (2021-09-14),

3. 10987362 - Treatment of fibrosis using FXR ligands (2021-04-27),

4. 10407462 - Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases (2019-09-10),

5. 10258633 - Treatment of fibrosis using FXR ligands (2019-04-16),

6. 9763964 - Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions (2017-09-19),

7. 9498484 - Treatment of fibrosis using FXR ligands (2016-11-22),

8. 9090652 - Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions (2015-07-28),

9. 8546365 - Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions (2013-10-01),

10. 8114858 - Derivatives of 4- or 5-aminosalicylic acid (2012-02-14),

11. 8114857 - Derivatives of 4- or 5-aminosalicylic acid (2012-02-14),

12. 7932244 - Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions (2011-04-26),

13. 7910568 - Derivatives of 4- or 5-aminosalicylic acid (2011-03-22),

14. 7879827 - Derivatives of 4- or 5-aminosalicylic acid (2011-02-01),

15. 7858608 - Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions (2010-12-28),

Title: The Innovative Contributions of Stefano Fiorucci

Introduction

Stefano Fiorucci is a prominent inventor based in Perugia, Italy, known for his significant contributions to pharmaceutical sciences. With a total of 16 patents to his name, Fiorucci has made remarkable advancements in the treatment and prevention of various diseases.

Latest Patents

Among his latest patents, Fiorucci has developed compounds such as Isoxazole as FXR receptor agonists. This invention relates to pharmaceutical compositions aimed at treating and preventing FXR-mediated diseases. Another notable patent involves cholane derivatives for use in the treatment and prevention of FXR and TGR5/GPBAR1 mediated diseases. These compounds, characterized by cholane scaffolds, represent a significant step forward in therapeutic options.

Career Highlights

Fiorucci has worked with reputable companies in the pharmaceutical industry, including Intercept Pharmaceuticals, Inc. and Antibe Therapeutics Inc. His work has focused on innovative solutions that address critical health challenges.

Collaborations

Throughout his career, Fiorucci has collaborated with esteemed colleagues such as Roberto Pellicciari and Mark Pruzanski. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking therapies.

Conclusion

Stefano Fiorucci's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a leading inventor. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.